Skip to main content
OpenTrials
Completed

NCT Number: NCT04858191

Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia

This study investigates the use of hyperpolarized 129Xe magnetic resonance imaging (MRI) in children with primary ciliary dyskinesia (PCD) in detecting ventilation defects. The investigators will establish the feasibility and reliability of this test and how it changes compared to other pulmonary function tests.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital for Sick Children

Toronto, Ontario, M5G1X8, Canada

About this study

Primary Ciliary Dyskinesia (PCD) is an autosomal recessive inherited disorder caused by defects in ciliary structure and/or function. Prevention or delaying disease progression requires medical therapies and routine lung function monitoring, with the goal of early initiation of medical therapies. Of course, this is contingent on recognizing early lung disease.

Current investigations for monitoring lung disease include pulmonary function tests (PFT), chest x rays and chest CTs. But each of these modalities are either not sensitive enough or expose the patient to ionizing radiation.

The investigators believe that hyperpolarized 129Xe MRI (HP Xe-MRI), new imaging modality, will be more sensitive then current tests and also avoid the need for ionizing radiation. To evaluate this, The investigators will compare HP Xe-MRI to PFT, when the patient is well and during a pulmonary exacerbation that is being treated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of PCD as having either (i) biallelic mutations in known PCD genes or (ii) classic transmission electron microscopy structural ciliary defect
  • Informed consent and verbal assent (as appropriate) provided by the participant's parent or legal guardian and the participant
  • Ages 6-18 years and able to perform reproducible spirometry and achieve a breath hold duration sufficient for MRI acquisition

Exclusion criteria

  • Any other cardiac or respiratory disease
  • Inability to perform a breath-hold of adequate duration for MRI acquisition
  • Medical instability that would preclude the ability to undergo the required investigations
  • FEV1 % predicted <40% on any PFT within last 2 months at time of consent
  • Use of supplementary oxygen
  • Severe claustrophobia
  • Pregnancy or lactation
  • Presence of metal implants or other MRI contraindications

Treatment and study plan

Primary outcomes

  1. Ventilation Defect Percentage (VDP)

    Time frame: Within 1 year of study initiation

    Reliability; initial test

  2. Ventilation Defect Percentage (VDP)

    Time frame: Within 1 week of initial test

    Reliability; re-test

  3. Ventilation Defect Percentage (VDP)

    Time frame: Within 48 hours of pulmonary exacerbation diagnosis

    VDP within 48h of pulmonary exacerbation diagnosis

  4. Ventilation Defect Percentage (VDP)

    Time frame: Within 48 hours of antibiotic completion

    VDP within 48h of antibiotic completion

Secondary outcomes

  1. Pulmonary function tests (PFTs)

    Time frame: Within 1 year of study initiation

    Reliability; initial test

  2. Pulmonary function tests (PFTs)

    Time frame: Within 1 week of initial test

    Reliability; re-test

  3. Pulmonary function tests (PFTs)

    Time frame: Within 48 hours of pulmonary exacerbation diagnosis

    PFT within 48h of pulmonary exaction diagnosis

  4. Pulmonary function tests (PFTs)

    Time frame: Within 48 hours of antibiotic completion

    PFT within 48h of antibiotic completion

Sponsors and collaborators

Lead sponsor

The Hospital for Sick Children

Other

Collaborators

  • Provincial Health Services Authority British Columbia

Registry information

Acronym: PCD MRI

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 26, 2021
Registry last updated
Oct 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.